Morgan Stanley raised the price target for the Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock from “an Equal-weight” to “an Overweight”. The rating was released on March 01, 2023, according to finviz. We previously noted in another research note published on December 22, 2022 by BTIG Research that reiterated the stock to a Buy with a price target of $160 for SRPT stock. The research report from UBS has upgraded the stock from Neutral to Buy, with a price target set at $158. The stock was resumed by Cantor Fitzgerald, who disclosed in a research note on April 04, 2022, to Overweight and set the price objective to $140. In their research brief published January 05, 2022, Needham analysts reiterated the Sarepta Therapeutics Inc. stock to Buy with a price target of $150.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Sarepta Therapeutics Inc. (NASDAQ:SRPT) raised 2.89% to close Thursday’s market session at $149.67, higher as compared to yesterday’s close. The stock price fluctuated between $143.75 and $150.805 throughout the trading session with the volume trading being 1755677 shares, which represented a significant variation when compared to the three months average volume of 1.22 million shares. The firm’s stock price fluctuated 0.83% within the last five trades and 24.35% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 39.14% in the last 6 months and 21.80% was added to its value over the previous 3 months. SRPT stock is trading at a margin of 8.76%, 16.12% and 37.14% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
As of the close of trading, SRPT deals in the Healthcare domain. The stock is trading -6.36 percent below its 52-week high and 144.24 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 81.4. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Sarepta Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at -71.20 percent and the profit margin is -75.40 percent, and the company has reported a gross margin of 85.00 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $13.58 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 31.19. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 14.56 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 34.17, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.20 percent of Sarepta Therapeutics Inc. shares are owned by insiders, and 89.10 percent are held by financial institutions. Mayo Stephen, the Director at Sarepta Therapeutics Inc. (SRPT) has sold 858 shares of firm on Nov 17 at a price of $109.92 against the total amount of $94311.0. In another inside trade, Chambers Michael Andrew, Director of Sarepta Therapeutics Inc. (NASDAQ:SRPT) bought 57,100 shares of the firm on Sep 14 for a total worth of $5.96 million at a price of $104.43. An inside trade which took place on Aug 19, Director of Sarepta Therapeutics Inc. Chambers Michael Andrew bought 46,170 shares of firm against total price of $5.0 million at the cost of $108.28 per share.